January 10, 2017
(Gizmodo) – By the time a panel of judges at the U.S. Patent and Trademark Office gets around to deciding who owns the biggest biotechnology innovation of the century, CRISPR-Cas9 may have already lost its heavyweight title as the most precise tool for genetic engineering. In the bitter patent battle between the Broad Institute and U.C. Berkeley that reached a courtroom climax last month, both institutions are duking it out for the right to claim that they invented CRISPR-Cas9, along with the right to reap millions and millions of dollars for licensing their discovery.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.